For the first time in the history of HIV prevention, people at risk of infection can be protected with just two injections a year. The U.S. Food and Drug Administration has approved lenacapavir — brand name Yeztugo — as a pre-exposure prophylaxis (PrEP) option, making it the only HIV prevention drug with a twice-yearly dosing schedule. Clinical trial data showed it stopped transmission in more than 99.9% of participants, a figure that stunned even veteran researchers in the field.
At a glance
- Lenacapavir HIV prevention: Gilead Sciences developed the drug, a capsid inhibitor that disrupts HIV at multiple points in its lifecycle — a mechanism distinct from every existing oral PrEP option on the market.
- Clinical trial results: The PURPOSE 1 and PURPOSE 2 Phase 3 studies, published in the New England Journal of Medicine, showed the shot outperformed daily oral PrEP and recorded near-zero transmission across tens of thousands of participants.
- Global access commitments: Gilead has signed royalty-free licensing agreements with six generic manufacturers to supply affordable versions of the drug to 120 countries, with priority given to high-burden regions in sub-Saharan Africa, Southeast Asia, and the Caribbean.
How lenacapavir HIV prevention works
Most existing PrEP medications block HIV at a single point in its replication cycle. Lenacapavir works differently. It belongs to a class called capsid inhibitors, which interfere with the virus at multiple stages simultaneously — disrupting how it enters cells, how it replicates, and how new viral particles assemble.
This layered mechanism makes resistance harder to develop. It also enables the drug’s long-acting formulation. The twice-yearly schedule is not a marketing convenience — it is a direct result of how the compound behaves in the body over time, remaining at protective concentrations for roughly six months after each injection.
Researchers had been working toward this kind of long-acting injectable PrEP for years. The science of the drug and the science of adherence were always understood as connected problems. The World Health Organization recommended lenacapavir as an additional PrEP option in 2024 C.E., a step that opens pathways for inclusion in national HIV prevention programs worldwide.
Why the dosing schedule is the breakthrough
Daily oral PrEP has been available since 2012 C.E. and, when taken consistently, is highly effective. Consistency is the hard part.
Stigma, unreliable clinic access, the psychological weight of a daily reminder, economic instability, and the simple reality of busy lives all erode adherence over time. The communities carrying the heaviest HIV burden are often the same ones facing the most barriers to daily medication routines. UNAIDS has described lenacapavir as a potential turning point precisely because it removes most of those friction points at once.
No daily pill. No visible medication to explain to a partner or a parent. Far fewer clinic visits. A twice-yearly injection restructures the entire prevention experience — and in public health, structural simplification has historically driven adoption far more than incremental efficacy gains alone.
Who participated and why it matters
The PURPOSE 1 trial enrolled primarily cisgender women in sub-Saharan Africa — a population that accounts for a disproportionate share of new HIV infections globally and one that has historically been underrepresented in the clinical research that shapes global drug policy. Their participation in a trial designed around their specific risk profile is a meaningful part of how this drug came to exist.
Sub-Saharan Africa accounts for roughly two-thirds of all people living with HIV worldwide. The PURPOSE 1 results, published in the New England Journal of Medicine, showed zero HIV infections among participants receiving lenacapavir, compared to infections in the oral PrEP comparison group. That outcome, in a high-prevalence population, is what gave regulators the confidence to move quickly.
The access question that remains open
Gilead’s royalty-free licensing deals with six generic manufacturers are a real commitment. They are also not enough on their own. Generic production takes time to scale. Distribution infrastructure in high-burden regions is uneven. The U.S. list price for branded lenacapavir is high, and advocates have pressed Gilead — and governments — to ensure affordability extends beyond the 120 countries named in the licensing agreements.
Roughly 1.3 million new HIV infections occur globally each year. The gap between what is approved and what actually reaches the people who need it is where many medical advances stall. Programs like PEPFAR and multilateral partnerships with organizations including Gavi have historically helped bridge that gap for antiretrovirals and vaccines — similar mechanisms will almost certainly be needed here to translate this approval into meaningful population-level impact.
The drug does not solve the structural inequities that drive HIV transmission. What it does is give prevention programs a genuinely new tool — one that works through a different mechanism, lasts longer, and asks considerably less of the people using it. In global health, that combination is rare.
Read more
For more on this story, see: AP News
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Ghana establishes new marine protected area at Cape Three Points
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
Rhinos return to Uganda’s wild after 43 years of absence
Uganda rhino reintroduction marks a historic milestone: wild rhinoceroses are roaming Ugandan soil for the first time in over 40 years. In 2026, rhinos bred at Ziwa Rhino Sanctuary were released into Kidepo Valley National Park, ending an absence caused entirely by poaching and political collapse during the Idi Amin era. The release represents decades of careful breeding, conservation funding, and community engagement. For local communities, conservationists, and a watching world, it proves that deliberate, sustained human effort can reverse even the most painful wildlife losses.
-
UK cancer death rates reach their lowest level ever recorded
Cancer death rates in the United Kingdom have fallen to the lowest level ever recorded, according to Cancer Research UK data published in 2026. Age-standardized mortality rates have dropped by more than 25% over the past two decades, driven by advances in lung, bowel, and breast cancer treatment and diagnosis. Expanded NHS screening programs, immunotherapy, and targeted drug therapies are credited as key factors behind the sustained decline. The achievement represents generations of compounding progress across research, clinical care, and public health, though significant inequalities in cancer survival persist across socioeconomic and geographic lines.
-
California condors nest on Yurok land in the Pacific Northwest for the first time in over a century
California condors are nesting in the Pacific Northwest for the first time in over a century, on Yurok Tribe territory in Northern California. The confirmed nest marks a landmark moment in condor recovery and represents deep cultural restoration for the Yurok people, who consider the condor — prey-go-neesh — a sacred relative. The Yurok Tribe has led reintroduction efforts since 2008, combining Indigenous ecological knowledge with conventional conservation science. Successful wild nesting signals the recovering population is crossing a critical threshold, demonstrating that Indigenous-led conservation produces measurable, meaningful results.
